All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Pre-transplant salvage options: bringing conventional versus novel combinations to practice 

Jun 6, 2019
Share:

During ASCO 2019, Chicago, US, Alison J Moskowitz, Memorial Sloan Kettering Cancer Center, New York, US, spoke to the Lymphoma Hub about pre-transplant salvage options: bringing conventional versus novel combinations to practice.

Dr. Moskowitz explains that the general approach for a patient that has relapsed or refactor disease after their frontline treatment for Hodgkin lymphoma (HL) is to give some kind of second-line therapy followed by consolidation with an autologous stem cell transplant and the choice of treatment is dependant upon the institution treating the patient. These treatments may include traditional therapies such as ICE, chemotherapy, or DHAP based regimes. However, now that there are newer regimes available for HL such as rituximab and checkpoint inhibitors these are now being considered when treating second-line therapy patients.

Pre-transplant salvage options: bringing conventional versus novel combinations to practice